Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for CervoMed (CRVO) over the last 6 years, with Q3 2025 value amounting to $995374.0.

  • CervoMed's Gains from Investment Securities rose 240591.37% to $995374.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $995374.0, marking a year-over-year increase of 240591.37%. This contributed to the annual value of $636802.0 for FY2024, which is 8226.94% up from last year.
  • CervoMed's Gains from Investment Securities amounted to $995374.0 in Q3 2025, which was up 240591.37% from $995374.0 recorded in Q2 2025.
  • Over the past 5 years, CervoMed's Gains from Investment Securities peaked at $995374.0 during Q2 2025, and registered a low of $274.0 during Q1 2022.
  • In the last 4 years, CervoMed's Gains from Investment Securities had a median value of $162250.0 in 2023 and averaged $388616.7.
  • As far as peak fluctuations go, CervoMed's Gains from Investment Securities plummeted by 7551.86% in 2024, and later skyrocketed by 240591.37% in 2025.
  • Quarter analysis of 4 years shows CervoMed's Gains from Investment Securities stood at $140040.0 in 2022, then soared by 149.48% to $349374.0 in 2023, then surged by 82.27% to $636802.0 in 2024, then skyrocketed by 56.31% to $995374.0 in 2025.
  • Its Gains from Investment Securities was $995374.0 in Q3 2025, compared to $995374.0 in Q2 2025 and $909448.0 in Q1 2025.